IMU (ASX) Ann: Quarterly Activities/Appendix 4C Cash Flow Report

Originally posted by Watmighthavben: ↑

My take on the quarterly activities report is that Imugene appear to be devoting much time to recruiting sites for their clinical trials when perhaps the focus needs to change toward educating oncologists and in turn recruiting patients to them. Historically speaking there appears to be a very slow take up in many of their clinical trials with participants always on the minimal side, despite the large number of sites in play. The FDA allows Imugene to recruit between 3 - 6 patients per cohort in some of their trials, only to find its always closer to 3 enrolled. We only now hear as at May 2023 of one patient enrolled in the much lauded OASIS Trial for solid tumours when close to 90 percent of all cancer patients suffer with solid tumour diagnosis. With the right information surely oncologists in the US let alone Australia would be jumping all over this for their patients. Likewise PD1 Vaxx, the Imprinter Trial and the supposed supply agreement with Roche. What there aren't enough lung cancer patients out there worthy of Professor Kauamaya's already successful B cell vaccine, and a subsequent update in this Quarterly Activities Report?

Imugene promises much at the commencement of these trials, but attaining an FDA IND and dosing the first patients is but a small part of the job done. Their Her-Vaxx Keytruda Combination Trial being but one example. Big Pharma is often seen spending large sums recruiting hundreds if not thousands of patients to their clinical trials (i.e, competitors Enhertu and Jemperli). I realise for whatever reason Imugene does not wish to hop on board with them in the early stage of drug development, but from where I sit with low participation numbers its beginning to hurt them. A slow boat to China may have been ok a decade ago, but now the world of cancer research is moving at a rapid clip. With quantum computing and AI on the uptick vaccines are being tried and tested in years, not decades. Within a few years these timelines may be reduced to months. I would like to see Imugene rapidly expand their existing clinical trials to amass much more meaningful data through larger sample sizes across the broad spectrum of cancer indications. After close to two years in the clinic the company's flagship candidate Vaxinia now has only 20 patients on ongoing therapy. Whilst that may be suitable for some, I see the sample size as being far too small given the drugs exciting potential pre clinically. Particularly now the CF33 TNBC Trial appears dead in the water.

A rethink of trial expansion, commercial direction and supply/partnership agreements is required from the top down if Imugene is to deliver on investor expectations. The shareholders I'm confident would support the necessary company expansion to create more of the aforementioned data, be it via the NASDAQ, partnership or out licensing route. But clearly decisions need to be made sooner rather than later. PD1 Vaxx and in particular their extensive oncolytic viral arm and ancillary products need a real "pick me up" when one assesses these activities from an objective viewpoint, as opposed to the subjective view of a rusted on shareholder.

DYOR Seek investment advice as and when required Opinions only

Expand

"Educating oncologists" about what exactly? People are talking as if imugene have had a trial with significant results.

No.	Vol.	Price($)
6	293847	6.0¢

No.

Vol.

Price($)

293847

6.0¢

Price($)	Vol.	No.
5.6¢	8815	1

Price($)

Vol.

No.

5.6¢

8815

No.	Vol.	Price($)
6	293847	0.060
8	1246871	0.059
13	1269835	0.058
12	1235878	0.057
18	1841276	0.056

No.

Vol.

Price($)

293847

0.060

1246871

0.059

1269835

0.058

1235878

0.057

1841276

0.056

Price($)	Vol.	No.
0.056	8815	1
0.058	8000	1
0.059	83300	3
0.060	269508	5
0.061	1797119	8

Price($)

Vol.

No.

0.056

8815

0.058

8000

0.059

83300

0.060

269508

0.061

1797119

(20min delay)
Last 5.9¢		Change 0.000(0.00%)		Mkt cap ! $431.8M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0


Last 5.8¢		Change 0.000 ( 1.86 %)
Open	High	Low	Volume
5.9¢	6.0¢	5.8¢	563625
Last updated 10.06am 07/06/2024 ?

"Educating oncologists" about what exactly? People are talking...

Featured News

Morella sharpens the drill bit for lithium targets at Tabba Tabba

Drilling at Dunnings picks up new copper-gold zone for Talisman in NSW

Frontier boosts project economic for Waroona with increased battery time and revenue

Daily Market News: ASX200 to edge higher ahead of public holiday | June 7, 2024

Ausgold raises $38M for Katanning Gold Project in WA

Buyers (Bids)

Sellers (Offers)

Featured News

"Educating oncologists" about what exactly? People are talking...

Featured News

Top Stories

Morella sharpens the drill bit for lithium targets at Tabba Tabba

Drilling at Dunnings picks up new copper-gold zone for Talisman in NSW

Frontier boosts project economic for Waroona with increased battery time and revenue

Daily Market News: ASX200 to edge higher ahead of public holiday | June 7, 2024

Ausgold raises $38M for Katanning Gold Project in WA

Buyers (Bids)

Sellers (Offers)

Featured News